AttendMe Owl Logo
AttendMe
Evidence Evolution
Upper GI SurgeryUpper GI Surgery

How This Evidence Evolved

Achalasia Treatment

From Pneumatic Dilation to POEM: Evolving Interventions for Esophageal Motility Disorders

32.2

Timeline

Inoue POEM
2010
European Achalasia Trial
2011
POEM vs LHM RCT
2019
ACG Clinical Guidelines: Diagnosis and Management of Achalasia
2020
European Achalasia Trial (10-year)
2024
Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

The European Achalasia Trial (2011) randomized 201 patients with newly diagnosed achalasia to pneumatic dilation or laparoscopic Heller myotomy (LHM) with Dor fundoplication. At 2 years, therapeutic success was 90% with LHM versus 86% with pneumatic dilation, without a significant difference (p=0.46). LHM did not show superior therapeutic success. The 10-year follow-up found 74% success with each treatment in the full analysis set and proposed both as initial treatments.
Proof

Landmark RCTs and pivotal trials that established the evidence base

Inoue and colleagues introduced peroral endoscopic myotomy (POEM) in 2010, performing the procedure in 17 consecutive achalasia patients. POEM achieved an endoscopic myotomy through a submucosal tunnel. In this first series, the dysphagia score fell from a mean of 10 to 1.3 and LES pressure from 52.4 to 19.9 mmHg, with no serious POEM-related complications; comparison with other therapies was still awaited. At 10 years, the European Achalasia Trial found pneumatic dilation and LHM equally effective (74% vs 74% success, p=0.84), and both can be proposed as initial treatment.
Extension

Follow-up studies, subgroup analyses, and real-world validation

The 2019 randomized trial compared POEM with LHM plus Dor fundoplication in 221 patients with symptomatic achalasia. At 2 years, clinical success was 83.0% versus 81.7% (difference 1.4 percentage points; 95% CI -8.7 to 11.4; p=0.007 for noninferiority). POEM was noninferior within the prespecified margin; this did not establish equivalence. Endoscopic reflux esophagitis at 24 months occurred in 44% versus 29%. The trial supports discussing symptom control and reflux when selecting treatment.
Guidelines

Integration into clinical practice guidelines and recommendations

ACG 2020: in definitive-therapy candidates, PD/LHM/POEM are options for types I/II; tailored POEM or LHM for type III. Select by patient preference and expertise; counsel higher GERD risk after POEM than LHM with fundoplication or PD.
ACG Clinical Guidelines: Diagnosis and Management of Achalasia

Definitive-therapy candidates: PD/LHM/POEM for types I/II; tailored POEM/LHM for type III.

ACG Clinical Guidelines: Diagnosis and Management of Achalasia

POEM and LHM give comparable symptom relief; counsel higher GERD risk after POEM vs LHM with fundoplication or PD.

Now

Current standard of care and ongoing research directions

Comparative trials address symptom control and reflux. PD and LHM each achieved 74% therapeutic success at 10 years in the European trial. POEM was noninferior to LHM plus Dor fundoplication at 2 years in a separate trial, with reflux esophagitis at 24 months in 44% versus 29%. What are the longer-term consequences of reflux, including Barrett’s esophagus risk? How should manometric subtype inform selection? What evidence supports endoscopic myotomy techniques for spastic esophageal disorders or Zenker’s diverticulum?

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

What is the most effective treatment for achalasia?+
Treatment choice depends on achalasia subtype, symptom control and reflux. Trials reported 2-year success of 90% with LHM versus 86% with PD, and 83.0% with POEM versus 81.7% with LHM plus Dor. The European trial reported 74% success at 10 years with each treatment (P=.84). POEM was noninferior to LHM plus Dor in the 2019 trial (P=.007); esophagitis at 24 months was 44% versus 29%. These trials do not establish one universally best treatment.
What is POEM and how does it differ from Heller myotomy?+
POEM (Peroral Endoscopic Myotomy), reported by Inoue and colleagues in 2010, performs endoscopic myotomy through a submucosal tunnel. The initial series included 17 patients, with reduced dysphagia scores and lower esophageal sphincter pressure. In the 2019 randomized comparison with LHM plus Dor fundoplication, POEM was noninferior for symptom control at 2 years, but endoscopic reflux esophagitis at 24 months was more frequent (44% vs 29%).

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026